Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 4596 clinical trials
Featured trial
CALGB 30610: Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide.

CALGB 30610: Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide.

  • 332 views
  • 08 Nov, 2020
  • 1 location
Featured trial
CCCWFU 99211: Feasibility of Delivering a quitline Based Smoking Cessation Intervention in Lung Cancer Patients Receiving Outpatient Treatment: A Pilot Study

CCCWFU 99211: Feasibility of Delivering a quitline Based Smoking Cessation Intervention in Lung Cancer Patients Receiving Outpatient Treatment: A Pilot Study

  • 259 views
  • 08 Nov, 2020
  • 1 location
Featured trial
A STUDY TO EVALUATE A PANEL OF BLOOD BIOMARKERS FOR USE IN PATIENTS UNDERGOING EVALUATION FOR LUNG CANCER, ONC-LN-04

A STUDY TO EVALUATE A PANEL OF BLOOD BIOMARKERS FOR USE IN PATIENTS UNDERGOING EVALUATION FOR LUNG CANCER, ONC-LN-04

  • 98 views
  • 23 Nov, 2020
  • 1 location
Featured trial
Featured trial
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation

Evaluates the safety, tolerability, pharmacokinetics, metabolites, pharmacodynamics, and clinical activity of MRTX849 in patients with advanced solid tumors with a KRAS G12C mutation. MRTX849 is an orally-available small molecule inhibitor of KRAS G12C.

solid tumor
malignant solid tumor
advanced solid tumor
  • 536 views
  • 22 Nov, 2021
  • 62 locations
Featured trial
A Phase 1/2 Trial of MRTX849 in Combination with TNO155 in Patients with Advanced Solid Tumors with KRAS G12C Mutation

Characterize the safety and tolerability, and evaluate Pharmacokinetics of MRTX849 in combination with TNO155 in patients with advanced solid tumor malignancies with KRAS G12C mutation. MRTX849 is an orally available small molecute inhibitor of KRASG12C. TNO155 is a selective, orally bioavailable allosteric inhibitor of wild type SHP2.

solid tumor
malignant solid tumor
solid tumors
advanced solid tumor
  • 178 views
  • 19 Feb, 2021
  • 4 locations
Featured trial
VastBiome: The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors

The microbiome has the potential to serve as a robust biomarker of clinical response to immunotherapy. Additionally, microbial manipulation, through diet, exercise, prebiotics, probiotics, or microbially-derived metabolites, may prove to be beneficial in promoting anti-tumor immune responses. However, large prospective studies in humans with longitudinal sample collection and standardized methods …

programmed cell death 1 ligand 1
cancer
targeted therapy
cancer chemotherapy
  • 0 views
  • 28 Feb, 2022
  • 1 location